Paper7514366
Risperidone in the treatment of schizophrenia.
Marder SR and 1 other. Am J Psychiatry, 1994. Cited by 1,080 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Risperidone in the treatment of schizophrenia. Papers, record 7514366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7514366
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Isoxazoles | Major topic |
| Piperidines | Major topic |
| Schizophrenia | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Double-Blind Method | |
| Drug Administration Schedule | |
| Female | |
| Haloperidol | |
| Humans | |
| Male | |
| Middle Aged | |
| Placebos | |
| Psychiatric Status Rating Scales | |
| Risperidone | |
| Schizophrenic Psychology | |
| Treatment Outcome |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00249132 | A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia | Results | ClinicalTrials.gov | |
| NCT05282277 | Examining the Effects of Estradiol on Neural and Molecular Response to Reward | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 7,542,836 | Risperidone for treatment-refractory schizophrenia. | https://conductscience.org/library/papers/7542836 |
Source PubMed
Cited by183
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,080 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,446,851 | Animal Models for Drug Discovery in Schizophrenia: A Critical View from a Clinical Perspective. | Pharmaceut Med | 2026 | https://conductscience.org/library/papers/42446851 | PubMed |
| 42,295,697 | A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use. | CNS Drugs | 2026 | https://conductscience.org/library/papers/42295697 | PubMed |
| 42,282,265 | The inhibitors of 17β-HSD10: are they any good? | RSC Chem Biol | 2026 | https://conductscience.org/library/papers/42282265 | PubMed |
| 42,110,904 | Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study. | Alpha Psychiatry | 2026 | https://conductscience.org/library/papers/42110904 | PubMed |
| 41,469,509 | Sex-specific transcriptome similarity networks elucidate comorbidity relationships. | Commun Med (Lond) | 2025 | https://conductscience.org/library/papers/41469509 | PubMed |
| 40,561,150 | Major adverse cardiac events with haloperidol: A meta-analysis. | PLoS One | 2025 | https://conductscience.org/library/papers/40561150 | PubMed |
| 40,149,518 | Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials. | Biomedicines | 2025 | https://conductscience.org/library/papers/40149518 | PubMed |
| 39,950,283 | An Emerging Prospective of Antipsychotics for Treating Neurodegenerative Disorders. | Curr Pharm Des | 2025 | https://conductscience.org/library/papers/39950283 | PubMed |
| 39,799,532 | Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape. | CNS Drugs | 2025 | https://conductscience.org/library/papers/39799532 | PubMed |
| 39,619,356 | Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids. | Psychiatry Clin Psychopharmacol | 2021 | https://conductscience.org/library/papers/39619356 | PubMed |
| 38,659,603 | Relationship between plasma risperidone concentrations and clinical features in chronic schizophrenic patients in China. | World J Psychiatry | 2024 | https://conductscience.org/library/papers/38659603 | PubMed |
| 38,200,532 | Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients. | BMC Psychiatry | 2024 | https://conductscience.org/library/papers/38200532 | PubMed |
| 37,867,639 | Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors. | ACS Omega | 2023 | https://conductscience.org/library/papers/37867639 | PubMed |
| 37,741,946 | Targeting metacognitive change mechanisms in acute inpatients with psychotic symptoms: feasibility and acceptability of a modularized group intervention. | Eur Arch Psychiatry Clin Neurosci | 2024 | https://conductscience.org/library/papers/37741946 | PubMed |
| 36,408,307 | Risperidone Abruption-Induced Tardive Dyskinesia in a Six-Year-Old Male Patient With Known Autism and Attention Deficit Hyperactivity Disorder: A Case Report. | Cureus | 2022 | https://conductscience.org/library/papers/36408307 | PubMed |
| 36,188,551 | Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36188551 | PubMed |
| 35,904,592 | Movement disorders of the mouth: a review of the common phenomenologies. | J Neurol | 2022 | https://conductscience.org/library/papers/35904592 | PubMed |
| 35,615,642 | Current and Possible Future Therapeutic Options for Huntington's Disease. | J Cent Nerv Syst Dis | 2022 | https://conductscience.org/library/papers/35615642 | PubMed |
| 35,547,105 | Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital. | S Afr J Psychiatr | 2022 | https://conductscience.org/library/papers/35547105 | PubMed |
| 35,137,229 | Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. | Schizophr Bull | 2022 | https://conductscience.org/library/papers/35137229 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| HALOPERIDOL | CHEMBL54 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL54 | ChEMBL |
| RISPERIDONE | CHEMBL85 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL85 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7514366
GET https://conductscience.org/api/papers/v1/7514366/cited_by?page=2